Live Breaking News & Updates on Total Cost Of Care

Stay updated with breaking news from Total cost of care. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Collaborative Strategies in Hemophilia A Care Cost Management

Russell P. Gollard, MD, FACP, explores effective collaboration among health care professionals, administrators, and specialty pharmacies in managing rare diseases like hemophilia A. ....

United States , Russellp Gollard , Hemophilia A , Total Cost Of Care , Prophylactic Treatment , Factor Eight , Cost Factors , Drug Costs , Healthcare Settings , Patient Populations , Administrative Expenses , Treatment Adverse Events ,

Factors Impacting Hemophilia A Care Costs

Russell P. Gollard, MD, FACP, discusses how the rising costs of managing hemophilia A are influenced by drug expenses, treatment efficacy, and adverse events, creating significant financial burdens across health care settings and patient populations. ....

Russellp Gollard , Hemophilia A , Total Cost Of Care , Prophylactic Treatment , Factor Eight , Cost Factors , Drug Costs , Healthcare Settings , Patient Populations , Administrative Expenses , Treatment Adverse Events ,

Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models

A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model. ....

United States , Oncology Care Model , Enhancing Oncology Model , Oncology Care , Medicare Oncology Care Model , American Journal , Managed Care , Total Cost Of Care ,

Impact of ICER Reports on Hemophilia Treatment Decisions

Russell P. Gollard, MD, FACP, analyzes the role of ICER reports in optimizing patient care and health care costs. ....

Russellp Gollard , Icer Reports , Population Health , Effective Treatment , Healthcare Cost , Newer Agents , Total Cost Of Care , Adverse Effects , Bleed Reduction , Monoclonal Antibody Impact ,

Coverage Decisions for Expensive Hemophilia Treatments

Russell P. Gollard, MD, FACP, discusses coverage decisions for expensive treatments in hemophilia, including total cost of care, drug availability, and real-world evidence. ....

Russellp Gollard , Coverage Decisions , Nexpensive Treatments , Hemophilia Patients , Total Cost Of Care , Real World Evidence , Gene Therapies , Drug Availability , Specialty Pharmacies , Treatment Efficacy , Side Effects Prevention ,